Translational Assessment of Vitiligo According to Body Locations — Vitiligo BL  

Vitiligo Clinical Trial

Official title: Translational Assessment of Vitiligo According to Body Locations Translational Study

Status Recruiting

Clinical Trial Summary

Vitiligo affects 0.5 to 2% of worldwide population and has a demonstrated impact on the quality of life.

Optimal treatment of vitiligo requires to target the auto-immune inflammatory response (to halt the depigmentation process), but also to induce the differentiation of melanocyte stem cells (to induce repigmentation). There is a well demonstrated discrepancy in the repigmentation response between anatomical areas of the body. Face and neck are the best responder with complete or almost complete repigmentation achieved in most cases under treatment. Trunk and limbs could have a complete or almost complete repigmentation in approximately half of the cases. The repigmentation is much more difficult in wrists, elbows, knees, proximal part of the hands. Finally, some areas such as the extremities of hands and feet, palms, soles, are almost impossible to repigment.

The investigator hypothesize that there are some factors that are produced in the skin that prevent (or at least decrease) the differentiation but also probably the migration and proliferation of melanocytes.

Primary objective To compare the mRNA expression of each types of cells in the skin of vitiligo patients compared to healthy volunteers according to body locations

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Vitiligo

• NCT number: NCT06068218
• Study type: Interventional
• Source: Centre Hospitalier Universitaire de Nice
• Contact: Passeron Thierry, PhD
• Phone: +33492036488
• Email: passeron.t@chu-nice.fr
• Status: Recruiting
• Phase: N/A
• Start date: July 2, 2024
• Completion date: October 2, 2025